Spruce Biosciences reported a significant increase in cash and cash equivalents to $87.7 million as of September 30, 2026, compared to $48.9 million at year-end 2025. However, the company faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $341.7 million and a need for additional financing to develop its lead product candidate, tralesinidase alfa (TA-ERT).
Spruce Biosciences reported Q3 2026 financial results and confirmed it remains on track to submit a Biologics License Application (BLA) for TA-ERT in December 2026. The company also amended its loan agreement with Avenue Capital to increase tranche availability to $15 million and announced the separation of its CRHX-101 program into a new entity, Adrenyx Biosciences.
Term
Q3 2026
“We are executing with discipline as we complete the final steps toward our planned BLA submission for TA-ERT in December, which we believe will be a defining milestone for Spruce and for the children and families living with MPS IIIB.”
Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences
“Our amended Avenue Loan Agreement expands our near-term access to debt capital and extends our interest-only period, giving us added financial flexibility as we move through BLA review and prepare for a potential U.S. commercial launch.”
Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences